)
Hyderabad-based drug maker Dr Reddy's Laboratories stated that it has launched Sirolimus tablets 1 mg and 2 mg, a therapeutic equivalent generic version of Rapamune tablets in the US market following the approval by the United States Food & Drug Administration (US FDA).
The Rapamune tablets brand had US sales of approximately $206 million for the most recent twelve months ending in August 2014 according to IMS Health. The drug is indicated for prevention of organ rejection in kidney transplant patients.
Dr Reddy's stated in a press release that its Sirolimus are available in bottle counts of 100.
